Pancreatic Cancer Research

ResearcherShanxi Medical UniversityActive in the last 2 years

Chengfeng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5589-7391; OpenAlex author ID A5101515225. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 13

  1. Retraction Note: ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experi… Last author DOI 10.1007/s10142-024-01373-4↗
  2. ITGA3 acts as a purity-independent biomarker of both immunotherapy and chemotherapy resistance in pancreatic cancer: bioinformatics and experimental analysis. Last author DOI 10.1007/s10142-023-01122-z↗
  3. Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. Last author DOI 10.1002/advs.202200818↗
  4. Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2021.04.007↗
  5. Preoperative Alkaline Phosphatase-to-Cholesterol Ratio as a Predictor of Overall Survival in Pancreatic Ductal Adenocarcinoma Patients Undergoing Radical Pancr… Last author DOI 10.12659/msm.931868↗
  6. Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection. Last author DOI 10.4240/wjgs.v13.i3.279↗
  7. Clinicopathological Features, Recurrence Patterns, and Prognosis of Pancreatic Adenocarcinoma with Normal Serum CA19-9. A Consecutive Series of 154 Cases from … First author DOI 10.1007/s11605-019-04209-w↗
  8. Equipping the American Joint Committee on Cancer Staging for Resectable Pancreatic Ductal Adenocarcinoma with Tumor Grade: A Novel Staging System. Last author DOI 10.1155/2020/9093729↗
  9. Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection. Last author DOI 10.3748/wjg.v26.i46.7382↗
  10. Experts' consensus on intraoperative radiotherapy for pancreatic cancer. Last author DOI 10.1016/j.canlet.2019.01.038↗
  11. Association of Genetic Polymorphisms in UDP-Glucuronosyltransferases 2B17 with the Risk of Pancreatic Cancer in Chinese Han Population. Co-author DOI 10.7754/clin.lab.2015.150329↗
  12. [Value of intraoperative radiotherapy in the treatment of locally advanced pancreatic cancer]. Co-author PMID 21418868↗
  13. [How to operate successfully for pancreatic cancer]. Co-author PMID 22340648↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongxing Du · 6 shared papers, 2020–2023 · strength 1.00
  2. Xiaohao Zheng · 4 shared papers, 2021–2024 · strength 0.89
  3. Hu Ren · 5 shared papers, 2020–2021 · strength 0.71
  4. Lipeng Zhang · 4 shared papers, 2020–2021 · strength 0.56
  5. Zongting Gu · 3 shared papers, 2021–2022 · strength 0.42
  6. Guotong Qiu · 3 shared papers, 2020–2021 · strength 0.39
  7. Mingyang Liu · 1 shared paper, 2024 · strength 0.31
  8. Mingyang Liu · 1 shared paper, 2023 · strength 0.26
  9. Yajie Zhao · 1 shared paper, 2020 · strength 0.24
  10. Jianwei Zhang · 3 shared papers, 2011–2021 · strength 0.21
  11. Guang Li · 2 shared papers, 2019–2021 · strength 0.19
  12. Lipeng Zhang · 1 shared paper, 2021 · strength 0.16
  13. Hebing Chen · 1 shared paper, 2022 · strength 0.16
  14. Xu Che · 3 shared papers, 2011–2019 · strength 0.16
  15. Chaorui Wu · 1 shared paper, 2020 · strength 0.13
  16. Yingtai Chen · 2 shared papers, 2015–2019 · strength 0.13
  17. Ke Xu · 1 shared paper, 2021 · strength 0.11
  18. Fei Li · 1 shared paper, 2019 · strength 0.08
  19. Shengping Li · 1 shared paper, 2019 · strength 0.08
  20. Jing Jin · 1 shared paper, 2019 · strength 0.08
  21. Ye‐Xiong Li · 1 shared paper, 2019 · strength 0.08
  22. Menghua Dai · 1 shared paper, 2019 · strength 0.08
  23. Rufu Chen · 1 shared paper, 2019 · strength 0.08
  24. Lei Zheng · 1 shared paper, 2019 · strength 0.08
  25. Jun Qi · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.